Ventyx Biosciences, Inc. (VTYX)
NASDAQ: VTYX · Real-Time Price · USD
1.610
-0.050 (-3.01%)
At close: Feb 21, 2025, 4:00 PM
1.650
+0.040 (2.48%)
After-hours: Feb 21, 2025, 7:57 PM EST
Ventyx Biosciences Employees
As of December 31, 2023, Ventyx Biosciences had 80 total employees, including 79 full-time and 1 part-time employees. The number of employees increased by 21 or 35.59% compared to the previous year.
Employees
80
Change (1Y)
21
Growth (1Y)
35.59%
Revenue / Employee
n/a
Profits / Employee
-$1,906,550
Market Cap
113.84M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 80 | 21 | 35.59% |
Dec 31, 2022 | 59 | 32 | 118.52% |
Dec 31, 2021 | 27 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
VTYX News
- 4 days ago - Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn's Disease at ECCO 2025 - GlobeNewsWire
- 17 days ago - Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 5 weeks ago - Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio - GlobeNewsWire
- 3 months ago - Ventyx Biosciences to Participate in Three Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Ventyx Biosciences: Ready To Escape "The Crash Cycle" - Seeking Alpha
- 5 months ago - Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences - Benzinga
- 6 months ago - Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson's Disease - GlobeNewsWire
- 6 months ago - Ventyx Biosciences Announces Departure of Chief Financial Officer - GlobeNewsWire